Conjugates of antibody to carcinoembryonic antigen (murine monoclonal antibody and affinity-purified heteroantibody) lined to the A chain of ricin are potent and specific cytotoxins for human colorectal adenocarcinoma cells. Several classes of agents, including UV inactivated adenovirus and carboxylic ionophores, produce specific and dramatic enhancement of anti-CEA immunotoxin effect on colorectal cancel cell lines. We propose to explore the effect of these potentiating agents on immunotoxin internalization and cytotoxic effect. Immunotoxin internalization will be studied by flow cytometric, and cell fractionation techniques. Effects of different chemical linkages, toxic A chains, and antibody fragments will be examined. By these methods we hope to better understand the process of immunotoxin effect and produce more rapidly acting and potent anti-tumor immunotoxins. We will also evaluate the anti-tumor effect of anti-CEA immunoconjugates in a well-characterized human tumor model in genetically athymic mide, the subrenal capsule assay. The tumoricidal capacity of immunoconjugates against human tumor colorectal xenografts will be examined in this system, and in a 6 day assay in immunocompetent mice. Effect of ionophores on the in vivo cytotoxicity of conjugates will be examined. Biodistribution studies indicate rapid immunotoxin clearance from the blood after intravenous injection in tumor-bearing animals. Immunotoxins show decreased tumor localization and increased hepatic clearance, in comparison to unconjugated antibody. This rapid clearance may be related to specific clearance by liver macrophages of immunotoxin, dictated by mannose and N-acetylglucosamine on ricin A chain. Liver non-parenchymal cells have specific receptors which bind and catabolize glycoproteins terminating in these carbohydrate residues. We propose to study the biodistribution and tumoricidal effect of immunoconjugates constructed with natural (abrin) or chemically modified (ricin) aglyco-A chains. We will determine if removal of carbohydrates from A chain improves the pharmacology, tumor localization, and tumoricidal ability of such aglycoimmunoconjugates. By these studies we hope to gain a better understanding of the mechanism of immunotoxin effect on tumor cells, and to alter the pharmacologic properties of immunotoxins to improve their in vivo tumor localization and tumoricidal effect.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA039748-02
Application #
3179145
Study Section
Experimental Immunology Study Section (EI)
Project Start
1985-09-30
Project End
1987-09-29
Budget Start
1986-09-30
Budget End
1987-09-29
Support Year
2
Fiscal Year
1986
Total Cost
Indirect Cost
Name
University of Massachusetts Medical School Worcester
Department
Type
Schools of Medicine
DUNS #
660735098
City
Worcester
State
MA
Country
United States
Zip Code
01655
Griffin, T; Rybak, M E; Recht, L et al. (1993) Potentiation of antitumor immunotoxins by liposomal monensin. J Natl Cancer Inst 85:292-8
Ito, T; Griffin, T W; Collins, J A et al. (1992) Intratumoral and whole-body distributions of C110 anti-carcinoembryonic antigen radioimmunotoxin after intraperitoneal and intravenous injection: a quantitative autoradiographic study. Cancer Res 52:1961-7
Griffin, T W; Stocl, M; Collins, J et al. (1992) Combined antitumor therapy with the chemotherapeutic drug doxorubicin and an anti-transferrin receptor immunotoxin: in vitro and in vivo studies. J Immunother (1991) 11:12-8
Maher, V E; Drukman, S J; Kinders, R J et al. (1992) Human antibody response to the intravenous and intraperitoneal administration of the F(ab')2 fragment of the OC125 murine monoclonal antibody. J Immunother (1991) 11:56-66
Aas, M; Mardirossian, G; Griffin, T W et al. (1992) Long-term biodistribution in tumored mice of murine and chimeric B72.3-IgG antibody radiolabeled with 114mIn via both DTPA and a macrocyclic chelator. J Nucl Biol Med 36:33-40
Levin, L V; Griffin, T W (1991) Specific adhesion of carcinoembryonic antigen-bearing colorectal cancer cells to immobilized carcinoembryonic antigen. Cancer Lett 60:143-52
Ito, T; Qiu, H; Collins, J A et al. (1991) Preclinical assessments of 90Y-labeled C110 anti-carcinoembryonic antigen immunotoxin: a therapeutic immunoconjugate for human colon cancer. Cancer Res 51:255-60
Griffin, T; Raso, V (1991) Monensin in lipid emulsion for the potentiation of ricin A chain immunotoxins. Cancer Res 51:4316-22
Griffin, T W; Brill, A B; Stevens, S et al. (1991) Initial clinical study of indium-111-labeled clone 110 anticarcinoembryonic antigen antibody in patients with colorectal cancer. J Clin Oncol 9:631-40
Hnatowich, D J; Rusckowski, M; Brill, A B et al. (1990) Pharmacokinetics in patients of an anti-carcinoembryonic antigen antibody radiolabeled with indium-111 using a novel diethylenetriamine pentaacetic acid chelator. Cancer Res 50:7272-8

Showing the most recent 10 out of 17 publications